NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?
NicOx plans to retain at least some rights to its late-stage osteoarthritis candidate. But can an R&D focused biotech do primary care?
NicOx plans to retain at least some rights to its late-stage osteoarthritis candidate. But can an R&D focused biotech do primary care?